Literature DB >> 2107278

Magnetic resonance imaging of the brain and spinal cord in cerebrotendinous xanthomatosis.

K S Bencze1, D R Vande Polder, L D Prockop.   

Abstract

This reports a 40 year old man with cerebrotendinous xanthomatosis who had bilateral cataracts, enlarged Achilles tendons, progressive dementia, gait disturbance and peripheral neuropathy. Electroencephalography, electromyography, and magnetic resonance imaging (MRI) of the brain and spine were performed. Magnetic resonance imaging revealed cerebral, cerebellar and cervical cord atrophy and white matter involvement in the cerebrum and cerebellum correlating well with the clinical findings. To date there has been one previous report of MRI of the brain in cerebrotendinous xanthomatosis and none of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107278      PMCID: PMC487959          DOI: 10.1136/jnnp.53.2.166

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Cerebrotendinous xanthomatosis. Clinical and pathological studies.

Authors:  J R Schimschock; E C Alvord; P D Swanson
Journal:  Arch Neurol       Date:  1968-06

2.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

3.  Magnetic resonance imaging in cerebrotendinous xanthomatosis.

Authors:  P D Swanson; L D Cromwell
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

4.  Psychiatric disorders in patients with cerebrotendinous xanthomatosis.

Authors:  V M Berginer; N L Foster; M Sadowsky; J A Townsend; G J Siegel; G Salen
Journal:  Am J Psychiatry       Date:  1988-03       Impact factor: 18.112

5.  Peripheral neuropathy in cerebrotendinous xanthomatosis.

Authors:  A Kuritzky; V M Berginer; A D Korczyn
Journal:  Neurology       Date:  1979-06       Impact factor: 9.910

6.  Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.

Authors:  G Salen; V Berginer; V Shore; I Horak; E Horak; G S Tint; S Shefer
Journal:  N Engl J Med       Date:  1987-05-14       Impact factor: 91.245

7.  Computed tomography in cerebrotendinous xanthomatosis.

Authors:  V M Berginer; J Berginer; G Salen; S Shefer; R D Zimmerman
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

8.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.

Authors:  G Salen; S M Grundy
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

  8 in total
  3 in total

1.  Cerebrotendinous xanthomatosis. Case report.

Authors:  O Bacchi; S Stefanucci; P L Brustenghi; A Pagliacci; G M Bellanti
Journal:  Ital J Neurol Sci       Date:  1992-09

2.  The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Antonio Federico; Nicola De Stefano; Marco Battaglini; Irene Grazzini; Paolo Galluzzi; Lucia Monti
Journal:  J Neurol       Date:  2017-03-21       Impact factor: 4.849

3.  Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients.

Authors:  Y Hokezu; M Kuriyama; R Kubota; M Nakagawa; J Fujiyama; M Osame
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.